Phase IIIEnrolling Remote Available

Semaglutide 2.4mg for Obesity Management in UAE Adults

Novo Nordisk UAE·NCT05712398·Obesity

Duration

15 months

Cost

Free to Patients

Phase

Phase III

Closes

Apr 2026

About This Trial

Evaluating the efficacy and safety of semaglutide 2.4mg weekly for weight management in UAE adult population.

Dubai, UAE

Abu Dhabi, UAE

Remote participation available, some or all visits can be done from home.

Condition focus: Obesity

Available in: UAE

All study medications and visits are provided at no cost to participants

Your health data is protected under HIPAA / GDPR / UAE PDPL regulations

You may withdraw from the trial at any time without penalty

Specific eligibility criteria (age ranges, lab values, prior medications) will be confirmed by the study coordinator after you express interest.

Trial Summary

NCT NumberNCT05712398

SponsorNovo Nordisk UAE

PhasePhase III

Duration15 months

ClosesApr 2026

ConditionObesity